Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

The creation of Open Payments Data (OPD) was formed from the Affordable Care Act to bring greater public transparency to the financial relationships between pharma and medical device companies, and healthcare providers. This white paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies, and ...

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, and Republicans expanding their majority in the Senate. Will there be bipartisan collaboration or political conflict and policy immobilism? This paper provides a detailed analysis why the US pharma industry, specifically ...

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Express Scripts merger, and partnering activities by Amazon, Berkshire Hathaway, and J.P. Morgan to get into the healthcare industry. These events taken together suggest what some have characterized as “the era of retail ...

It is widely believed that machine learning and data mining are right on the cusp of becoming among the most important breakthroughs that the healthcare industry has seen in years. While applications of these techniques have already occurred elsewhere in the pharma sector, wide-spread applications in pharmaceutical commercial analytics have come more recently. Pharma companies are now looking to ...

Access to Healthcare Practitioners (HCPs) continues to be restricted in this ever-evolving healthcare ecosystem. Contact with stakeholders is typically limited due to stringent anti-rep policies and their organization’s rules and guidelines. This calls for new ways to reach these stakeholders and the evolution of pharmaceutical call planning. This white paper explores the factors used to develop ...

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (DTCA), with the likely exception being drug pricing. Despite criticisms and the heated debate on the appropriateness of this channel, DTCA spending continues to grow. The drug industry spent approximately $5.6 billion on ...

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision science technologies and whether there should be focus on certain areas of expertise that are felt to offer a competitive advantage for the company? These choices in the direction of investments are embodied in the title of ...

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines that use new scientific drug delivery systems, e.g., large molecules as opposed to traditional small molecule drugs, catering to smaller patient populations. While this shift solves some problems pharma has been facing, ...

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white paper addresses is what could this policy, if enacted, have on the structure of US and global drug pricing and associated market effects? Specific projected effects are highlighted for both the US and global pharma ...